Targeting CDC7 sensitizes resistance melanoma cells to BRAFV600E-specific inhibitor by blocking the CDC7/MCM2-7 pathway
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting CDC7 sensitizes resistance melanoma cells to BRAFV600E-specific inhibitor by blocking the CDC7/MCM2-7 pathway
Authors
Keywords
-
Journal
Scientific Reports
Volume 9, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-10-02
DOI
10.1038/s41598-019-50732-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Extracellular vesicles and anti-Cancer drug resistance
- (2018) Niamh Mc Namee et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Cell division cycle 7 is a potential therapeutic target in oral squamous cell carcinoma and is regulated by E2F1
- (2018) Shufang Jin et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Prognostic Role of BRAFV600E Cellular Localization in Melanoma
- (2018) Zakaria Y. Abd Elmageed et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- First-in-human phase 1 study of TAK-931, an oral cell division cycle 7 (CDC7) inhibitor, in patients (pts) with advanced solid tumors.
- (2018) Toshio Shimizu et al. JOURNAL OF CLINICAL ONCOLOGY
- Nuclear PGK1 Alleviates ADP-Dependent Inhibition of CDC7 to Promote DNA Replication
- (2018) Xinjian Li et al. MOLECULAR CELL
- Immunohistochemistry as an accurate tool for evaluating BRAF-V600E mutation in 130 samples of papillary thyroid cancer
- (2017) Zakaria Y. Abd Elmageed et al. SURGERY
- Rescue of cell cycle progression in BRAFV600E inhibitor–resistant human melanoma by a chromatin modifier
- (2017) Antoni X Torres-Collado et al. TUMOR BIOLOGY
- NRAS-mutant melanoma: current challenges and future prospect
- (2017) Eva Muñoz-Couselo et al. OncoTargets and Therapy
- BRAF inhibitors: resistance and the promise of combination treatments for melanoma
- (2017) Merope Griffin et al. Oncotarget
- Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF
- (2017) Jae-Hyeon Kim et al. Cancer Research and Treatment
- DDK Promotes Tumor Chemoresistance and Survival via Multiple Pathways
- (2017) Nanda Kumar Sasi et al. NEOPLASIA
- A novel CDC7-selective inhibitor TAK-931 with potent antitumor activity
- (2016) K. Iwai et al. EUROPEAN JOURNAL OF CANCER
- Cell Cycle Phase-Specific Drug Resistance as an Escape Mechanism of Melanoma Cells
- (2016) Kimberley A. Beaumont et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways
- (2016) Xiaoyan Sun et al. Oncotarget
- MicroRNA expression profiles of drug-resistance breast cancer cells and their exosomes
- (2016) Shanliang Zhong et al. Oncotarget
- MiR-630 inhibits proliferation by targeting CDC7 kinase, but maintains the apoptotic balance by targeting multiple modulators in human lung cancer A549 cells
- (2014) J-X Cao et al. Cell Death & Disease
- Effect of dabrafenib on melanoma cell lines harbouring the BRAF V600D/R mutations
- (2013) Giusy Gentilcore et al. BMC CANCER
- Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells
- (2013) Kaitlyn Le et al. Pigment Cell & Melanoma Research
- Neoplastic Reprogramming of Patient-Derived Adipose Stem Cells by Prostate Cancer Cell-Associated Exosomes
- (2013) Zakaria Y. Abd Elmageed et al. STEM CELLS
- BRAF Inhibitors for the Treatment of Metastatic Melanoma: Clinical Trials and Mechanisms of Resistance
- (2012) A. M. Alcala et al. CLINICAL CANCER RESEARCH
- SHOC2 and CRAF Mediate ERK1/2 Reactivation in Mutant NRAS-mediated Resistance to RAF Inhibitor
- (2012) Fred M. Kaplan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Vemurafenib: the first drug approved for BRAF-mutant cancer
- (2012) Gideon Bollag et al. NATURE REVIEWS DRUG DISCOVERY
- NRAS mutant melanoma: biological behavior and future strategies for therapeutic management
- (2012) I V Fedorenko et al. ONCOGENE
- Targeting the RAS pathway in melanoma
- (2011) Zhenyu Ji et al. TRENDS IN MOLECULAR MEDICINE
- Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail
- (2010) Gajanan S. Inamdar et al. BIOCHEMICAL PHARMACOLOGY
- Targeting Cell Division Cycle 7 Kinase: A New Approach for Cancer Therapy
- (2010) A. Montagnoli et al. CLINICAL CANCER RESEARCH
- How do Cdc7 and cyclin-dependent kinases trigger the initiation of chromosome replication in eukaryotic cells?
- (2010) K. Labib GENES & DEVELOPMENT
- Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032
- (2010) Jonas N Søndergaard et al. Journal of Translational Medicine
- Hyperactivation of MEK–ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells
- (2010) F M Kaplan et al. ONCOGENE
- Dbf4-Cdc7 Phosphorylation of Mcm2 Is Required for Cell Growth
- (2009) Irina Bruck et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi
- (2008) Loren E. Clarke et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Understanding Signaling Cascades in Melanoma
- (2008) Pablo Lopez-Bergami et al. PHOTOCHEMISTRY AND PHOTOBIOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started